FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRalpha-positive, Platinum-Resistant Ovarian Cancer. Dilawari A, Shah M, Ison G, Gittleman H, et al. Clin Cancer Res 2023 May 22:CCR-23-0991. doi: 10.1158/1078-0432.CCR-23-0991.

Read + Share

Amedeo Smart

Independent Medical Education

Dilawari A, Shah M, Ison G, Gittleman H, et al. FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRalpha-positive, Platinum-Resistant Ovarian Cancer. Clin Cancer Res 2023 May 22:CCR-23-0991. doi: 10.1158/1078-0432.CCR-23-0991.
PMID: 37212825